Measuring ACPA in the general population or primary care: Is it useful?

16Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Rheumatoid arthritis (RA) is associated with a significant disease burden and high costs for society. Because the disease has identifiable preclinical stages, screening and prevention have become a possibility in RA. Anticitrullinated peptide antibodies (ACPAs) are arguably the most likely candidate biomarker to screen for RA. This paper reviews the evidence for the use of ACPAs as a screening test in the broader general population, to identify individuals at high risk of subsequent onset of RA. We will review the diagnostic properties of the test and its positive and negative predictive value in different settings. We will discuss how ACPA testing could effectively be integrated in a broader screening strategy for RA.

Cite

CITATION STYLE

APA

Finckh, A., Courvoisier, D., & Lamacchia, C. (2020, February 19). Measuring ACPA in the general population or primary care: Is it useful? RMD Open. BMJ Publishing Group. https://doi.org/10.1136/rmdopen-2019-001085

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free